Tirzepatide (50 mg)

What is Tirzepatide (50 mg)?

Tirzepatide (50 mg) is a synthetic peptide designed for advanced research in metabolic and hormone-signaling pathways. As a dual agonist, it targets both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors in experimental models. This dual-receptor activity provides a unique opportunity to study integrated incretin signaling and its role in regulating metabolic processes.

The peptide is engineered with specific amino acid substitutions, including Aib (α-aminoisobutyric acid) residues, and features a C20 fatty acid side-chain modification. These structural enhancements improve molecular stability and enable prolonged receptor interaction, enabling sustained signaling compared with native incretin hormones.

The 50 mg format is ideal for large-scale research programs, extended experimental series, and multi-phase studies requiring consistent peptide supply and reproducibility. Tirzepatide (50 mg) is for laboratory research use only and is not intended for clinical or therapeutic applications.

Product Specifications

• Synonyms: LY3298176, P1206, tirzepatida, tirzepatidum
• CAS Number: 2023788-19-2
• Molecular Formula: C₂₂₅H₃₄₈N₄₈O₆₈
• Molecular Weight:4813.48 g/mol g/mol
• Peptide Sequence:
  Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys-Ile-Ala-Gln-Lys(C20)-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH₂
• Purity: ≥95% (verified by HPLC and mass spectrometry)
• Packaging Format: 50 mg lyophilized powder in a sealed research-grade vial
• Storage Conditions: Store 2–8 °C (≤–20 °C long term). Protect from light.
• Intended Use: For Laboratory Research Use Only

Key Characteristics of Tirzepatide (50 mg)

• Dual incretin receptor-targeted peptide for metabolic research
• Designed to activate both GIP and GLP-1 receptors in controlled experimental models
• C20 fatty acid side-chain modification supports enhanced molecular stability and prolonged receptor interaction
• Amino acid substitutions increase resistance to enzymatic degradation
• High purity confirmed through HPLC and mass spectrometry
• Lyophilized form preserves structural integrity before reconstitution
• Ideal for in vitro studies and preclinical metabolic research models

How Tirzepatide (50 mg) Supports Research

Tirzepatide (50 mg) is used in laboratory experiments to study the dual activation of GIP and GLP-1 receptors. This enables researchers to investigate coordinated intracellular signaling cascades, including cAMP activation and metabolic pathway modulation.

The peptide’s structural stability enables evaluation of sustained receptor engagement and prolonged signaling activity. It is commonly incorporated into cellular assays and preclinical models to explore receptor dynamics and hormone–receptor interactions, and to conduct comparative analyses with other incretin-based peptides.

Research Applications & Usage Information

Tirzepatide (50 mg) is typically used in laboratory research involving:

• Dual GIP and GLP-1 receptor signaling investigations
• Glucose metabolism and endocrine communication studies
• Energy balance and metabolic pathway modeling
• Cellular signal transduction and second-messenger pathway analysis
• Comparative research on long-acting incretin analogs
• Preclinical metabolic disorder research models
• Hormone–receptor binding and pharmacodynamic evaluations

All uses are investigational and restricted to controlled laboratory research environments.

Handling and Storage Recommendations

• Store 2–8 °C (≤–20 °C for long-term storage). Protect from light exposure.
• Keep vials tightly sealed and protected from moisture until reconstitution.
• Allow the vial to equilibrate before opening to minimize exposure to condensation.
• After reconstitution, store solutions at 2–8 °C according to laboratory protocol.
• Avoid repeated freeze-thaw cycles to support research applications.
• Use sterile laboratory techniques during preparation and experimentation.

Research Use Only Notice

This product is intended for laboratory research use only and is not approved for human or veterinary use. It is not intended for diagnostic, therapeutic, or clinical applications. Any reference to biological activity or potential effects is based solely on preclinical or in vitro findings and should not be interpreted as validated clinical outcomes. Researchers are responsible for ensuring proper handling, storage, and disposal in accordance with institutional, federal, and international guidelines.

References

1. Willard FS, Douros JD, Gabe MB, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020;5(17):e140532. Published 2020 Sep 3. doi:10.1172/jci.insight.140532
2. Fisman EZ, Tenenbaum A. The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect. Cardiovasc Diabetol. 2021;20(1):225. Published 2021 Nov 24. doi:10.1186/s12933-021-01412-5
3. Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018;18:3-14. doi:10.1016/j.molmet.2018.09.009